Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86


Discovery of survivin inhibitors and beyond: FL118 as a proof of concept.

Li F.

Int Rev Cell Mol Biol. 2013;305:217-52. doi: 10.1016/B978-0-12-407695-2.00005-6. Review.


A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.

Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F.

PLoS One. 2012;7(9):e45571. doi: 10.1371/journal.pone.0045571. Epub 2012 Sep 19.


Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.

Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG, Li F.

Int J Biochem Mol Biol. 2012;3(2):179-97. Epub 2012 May 18.


The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response.

Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL, Newton DL.

Cancer Chemother Pharmacol. 2012 Jul;70(1):207-12. doi: 10.1007/s00280-012-1868-0. Epub 2012 Apr 21. Erratum in: Cancer Chemother Pharmacol. 2012 Nov;70(5):763-4.


Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by survivin is at least partially p53-dependent: evidence for survivin acting as a transcription factor or co-factor.

Tang L, Ling X, Liu W, Das GM, Li F.

Biochem Biophys Res Commun. 2012 May 4;421(2):249-254. doi: 10.1016/j.bbrc.2012.03.147. Epub 2012 Apr 6.


Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin.

Yoon MJ, Park SS, Kang YJ, Kim IY, Lee JA, Lee JS, Kim EG, Lee CW, Choi KS.

Carcinogenesis. 2012 Mar;33(3):492-500. doi: 10.1093/carcin/bgr298. Epub 2011 Dec 9.


Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.

Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MH, Eldering E.

Clin Cancer Res. 2012 Jan 15;18(2):487-98. doi: 10.1158/1078-0432.CCR-11-1440. Epub 2011 Nov 29.


Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.

Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M, Nakagawa K.

Mol Cancer Ther. 2012 Jan;11(1):204-13. doi: 10.1158/1535-7163.MCT-11-0638. Epub 2011 Nov 10.


A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.

Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S, Papadopoulos KP.

Cancer. 2012 Jun 15;118(12):3128-34. doi: 10.1002/cncr.26510. Epub 2011 Oct 17. Erratum in: Cancer. 2012 Sep 1;118(17):4365. Papadopoulos, Kyriakos P [added].


Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma.

Nagata M, Nakayama H, Tanaka T, Yoshida R, Yoshitake Y, Fukuma D, Kawahara K, Nakagawa Y, Ota K, Hiraki A, Shinohara M.

Br J Cancer. 2011 Oct 25;105(9):1322-30. doi: 10.1038/bjc.2011.387. Epub 2011 Sep 27.


A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer.

Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A, de Bono JS.

Ann Oncol. 2012 Apr;23(4):968-73. doi: 10.1093/annonc/mdr353. Epub 2011 Aug 22.


Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.

Montazeri Aliabadi H, Landry B, Mahdipoor P, Uludağ H.

Mol Pharm. 2011 Oct 3;8(5):1821-30. doi: 10.1021/mp200176v. Epub 2011 Aug 23.


Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.

Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM.

Blood. 2011 Aug 25;118(8):2191-9. doi: 10.1182/blood-2011-04-351239. Epub 2011 Jun 28.


YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.

Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T, Koutoku H, Sasamata M.

Anticancer Drugs. 2011 Jun;22(5):454-62. doi: 10.1097/CAD.0b013e328344ac68.


Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.

Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N, Sasamata M.

Leuk Res. 2011 Jun;35(6):787-92. doi: 10.1016/j.leukres.2010.11.016. Epub 2011 Jan 14.


Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M, Sasamata M.

Cancer Sci. 2011 Mar;102(3):614-21. doi: 10.1111/j.1349-7006.2010.01834.x. Epub 2011 Jan 12.


Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.

Li QF, Yan J, Zhang K, Yang YF, Xiao FJ, Wu CT, Wang H, Wang LS.

Biochem Biophys Res Commun. 2011 Feb 4;405(1):31-6. doi: 10.1016/j.bbrc.2010.12.111. Epub 2010 Dec 30.


cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer.

Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC, Goan YG, Lee H.

Clin Cancer Res. 2010 Nov 1;16(21):5200-10. doi: 10.1158/1078-0432.CCR-10-0020. Epub 2010 Oct 19.


Survivin and IAP proteins in cell-death mechanisms.

Altieri DC.

Biochem J. 2010 Sep 1;430(2):199-205. doi: 10.1042/BJ20100814. Review.


Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis.

Rückert F, Samm N, Lehner AK, Saeger HD, Grützmann R, Pilarsky C.

BMC Cancer. 2010 Jul 20;10:379. doi: 10.1186/1471-2407-10-379.

Supplemental Content

Support Center